In 2003 the Canadian recommendations for the management and treatment of dyslipidemia were revised – but further revisions are in order, argue Manuel and colleagues in a commentary in this issue of CMAJ.
The authors argue that the current guidelines may lead to more people who are at low risk of coronary artery disease being screened and prescribed statin therapy, which will increase cost for little overall benefit.
Jacques Genest and colleagues, members of the Working Group on Hypercholesterolemia and Other Dyslipidemias, comment on the data used by Manuel and colleagues and question their approach. A rebuttal from the challengers concludes the debate.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
Believe that life is worth living and your belief will help create the fact.
-- William James